Cambium Bio Limited has released a press release.
Japan Update
Filed with ASX ·
On 6ix: 6ix.com/news/japan-update
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- Regeneus receives R&D tax incentive refund of $2.7m
- Appendix 4E and Annual Report 2016
- European patent to grant on stem cell secretions for acne
- ARC grant to progress stem cell research for chronic pain
- Enrolment complete and positive safety in Progenza trial
Later from Cambium Bio
- Regeneus and AGC collaborate on Progenza in Japan
- Regeneus receives upfront payment of US$5.5m from AGC
- Chinese patent granted on stem cell secretions technology
- Positive clinical trial results for Progenza
- Japanese Patent Office to grant key patent for Progenza
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio